first-in-class, bioavailable BCL-XL inhibitor oral efficacy in xenograft, led to ADC dev. from SBDD of prior BH3 mimetics ACS Med. Chem. Lett., Jul. 5, 2020 AbbVie, North Chicago, IL / Genentech